Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125265681 | 12526568 | 1 | I | 20160627 | 20160705 | 20160705 | EXP | PHHY2016BR091377 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160705 | OT | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125265681 | 12526568 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | PATCH 10 (CM2), QD | U | 689210 | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | ||||
| 125265681 | 12526568 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | U | 22083 | TRANS-THERAPEUTIC-SYSTEM | ||||||||||
| 125265681 | 12526568 | 3 | SS | EXELON PATCH | RIVASTIGMINE | 1 | U | 22083 | TRANS-THERAPEUTIC-SYSTEM |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125265681 | 12526568 | 1 | Hypertension |
| 125265681 | 12526568 | 2 | Dementia Alzheimer's type |
| 125265681 | 12526568 | 3 | Parkinson's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125265681 | 12526568 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125265681 | 12526568 | Abasia | |
| 125265681 | 12526568 | Musculoskeletal stiffness | |
| 125265681 | 12526568 | Product use issue | |
| 125265681 | 12526568 | Terminal state |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |